Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 405

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Antibacterial Envelope to Prevent Cardiac Implantable Device Infection

Open access
Tarakji, Khaldoun G., Mittal, Suneet, Kennergren, Charles, Corey, Ralph, Poole, Jeanne E., Schloss, Edward, Gallastegui, Jose, Pickett, Robert A., Evonich, Rudolph, Philippon, François, McComb, Janet M., Roark, Steven F., Sorrentino, Denise, Sholevar, Darius, Cronin, Edmond, Berman, Brett, Riggio, David, Biffi, Mauro, Khan, Hafiza, Silver, Marc T., Collier, Jack, Eldadah, Zayd, Wright, David J., Lande, Jeff D., Lexcen, Daniel R., Cheng, Alan, Wilkoff, Bruce L. · 2019 · New England Journal of Medicine

Abstract

BACKGROUND: Infections after placement of cardiac implantable electronic devices (CIEDs) are associated with substantial morbidity and mortality. There is limited evidence on prophylactic strategies, other than the use of preoperative antibiotics, to prevent such infections. METHODS: We conducted a randomized, controlled clinical trial to assess the safety and efficacy of an absorbable, antibiotic-eluting envelope in reducing the incidence of infection associated with CIED implantations. Patients who were undergoing a CIED pocket revision, generator replacement, or system upgrade or an initial implantation of a cardiac resynchronization therapy defibrillator were randomly assigned, in a 1:1 ratio, to receive the envelope or not. Standard-of-care strategies to prevent infection were used in all patients. The primary end point was infection resulting in system extraction or revision, long-term antibiotic therapy with infection recurrence, or death, within 12 months after the CIED implantation procedure. The secondary end point for safety was procedure-related or system-related complications within 12 months. RESULTS: A total of 6983 patients underwent randomization: 3495 to the envelope group and 3488 to the control group. The primary end point occurred in 25 patients in the envelope group and 42 patients in the control group (12-month Kaplan-Meier estimated event rate, 0.7% and 1.2%, respectively; hazard ratio, 0.60; 95% confidence interval [CI], 0.36 to 0.98; P = 0.04). The safety end point occurred in 201 patients in the envelope group and 236 patients in the control group (12-month Kaplan-Meier estimated event rate, 6.0% and 6.9%, respectively; hazard ratio, 0.87; 95% CI, 0.72 to 1.06; P<0.001 for noninferiority). The mean (±SD) duration of follow-up was 20.7±8.5 months. Major CIED-related infections through the entire follow-up period occurred in 32 patients in the envelope group and 51 patients in the control group (hazard ratio, 0.63; 95% CI, 0.40 to 0.98). CONCLUSIONS: Adjunctive use of an antibacterial envelope resulted in a significantly lower incidence of major CIED infections than standard-of-care infection-prevention strategies alone, without a higher incidence of complications. (Funded by Medtronic; WRAP-IT ClinicalTrials.gov number, NCT02277990.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1901111

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 405

Metadata

Authors
Tarakji, K. G., Mittal, S., Kennergren, C., Corey, R., Poole, J. E., Schloss, E., Gallastegui, J., Pickett, R. A., Evonich, R., Philippon, F., McComb, J. M., Roark, S. F., Sorrentino, D., Sholevar, D., Cronin, E., Berman, B., Riggio, D., Biffi, M., Khan, H., Silver, M. T., Collier, J., Eldadah, Z., Wright, D. J., Lande, J. D., Lexcen, D. R., Cheng, A., & Wilkoff, B. L.
Venue
New England Journal of Medicine
Published
2019-05-16
Volume
380
Issue
20
Pages
1895-1905
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2920877797
Cited by
405
References
23
FWCI
32.46
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.